Hypoxia and Interleukin-6 Exacerbate Blood Coagulation in COVID-19 Patient.

Visit for more related articles at Journal of Lung


A hallmark of Coronavirus disease 2019 (COVID-19) is abnormalities in coagulation associated with up regulations in procoagulants that are indicators of high mortality. Critical illness is the main contributor to death due to COVID-19. COVID-19 has a multitude of comorbidities that vary among patients and with the severity at which they experience the virus. However, a common COVID-19 comorbidity is respiratory insufficiency resulting in hypoxemia .Hypoxemia increases the risk of thrombosis because of interference in regulation of blood coagulation. Coagulation is quite common in severely ill COVID-19 patients [4]. Coagulation is tightly regulated by the clotting factors, cofactors, and inhibitors that are associated with the control of the crucial enzyme thrombin. Haemostasis is a physiological state that aids to maintain and promote blood flow and prevents coagulation under normal circumstances. Conversely, in the event of an injury to a blood vessel, to minimize blood loss, a cascade of coagulation events takes place to maintain normal blood flow through the lumen of the damaged vessel.

Select your language of interest to view the total content in your interested language

Viewing options

Recommended Conferences
Flyer image

Share This Article